Background and aims: The association between inflammatory bowel diseases (IBD) and cardiovascular disease (CVD) remains equivocal. Arterial stiffness, as assessed by pulse wave velocity (PWV), and lipoprotein-associated phospholipase A2 (Lp-PLA2) are surrogates of CVD risk. Aim: The aim of this study was to assess carotid-femoral PWV and Lp-PLA2 in patients with IBD without history of CVD. Methods: Established CVD risk factors, IBD characteristics, PWV and Lp-PLA2 activity were assessed in 44 patients with IBD, 29 with Crohn's disease (CD) and 15 with ulcerative colitis (UC), and 44 matched controls. Results: IBD patients had lower total and low density lipoprotein cholesterol (LDL-C) levels. There was no difference in PWV between patients and controls (6.8 vs 6.4 m/s), but patients with CD had higher PWV compared to those with UC (7 vs 6.3 m/s; p = 0.044), and to controls. Smoking rates were significantly higher among CD patients. Factors associated with PWV were age, mean arterial pressure and smoking. Lp-PLA2 activity was significantly lower in patients Abbreviations: CVD, cardiovascular disease; CRP, C-reactive protein; IBD, inflammatory bowel diseases; CAD, coronary artery disease; PWV, pulse wave velocity; AIx, augmentation index; Lp-PLA2, lipoprotein-associated phospholipase A2; LDL, low density lipoprotein; CD, Crohn's disease; UC, ulcerative colitis; BMI, body mass index; BP, blood pressure; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; CDAI, Crohn's Disease Activity Index; MAP, mean arterial pressure; SD, standard deviation; 5-ASA, 5-aminosalicylates; TNF-a, tumour necrosis factor-a.
Introduction
Our insight into the pathogenesis of atherosclerosis has shifted in the last decade from plain accumulation of lipids within the arterial wall to the concept of atherogenesis as an inflammatory process. 1 Traditional cardiovascular disease (CVD) risk factors, such as smoking, hypertension, diabetes mellitus and dyslipidaemia, result in endothelial dysfunction, which precipitates macrophage and T cell accumulation, release of chemokines, adhesion molecules and pro-inflammatory cytokines. 2 Inflammatory markers increase in the systemic circulation as a result of this process, with C-reactive protein (CRP) being the most extensively studied molecule. 3 Systemic inflammation is an independent risk factor for CVD, as has been eloquently demonstrated by the increased incidence of CVD in patients with rheumatoid arthritis and systemic lupus erythematosus, that cannot be attributed to traditional CVD risk factors. 4, 5 It has been hypothesized that pro-inflammatory cytokines may precipitate alterations in lipid concentrations, hyperhomocysteinaemia, oxidative stress, insulin resistance, and endothelial dysfunction, changes that are considered pro-atherogenic. 5 In the case of inflammatory bowel diseases (IBD), which are also characterized by chronic systemic inflammation, the association with CVD risk remains equivocal. No prospective epidemiological studies have assessed the incidence of CVD and/or CVD events in patients with IBD. Retrospective studies with significant methodological caveats have shown increased incidence of coronary artery disease (CAD) in IBD patients. 6, 9 The largest cohort of approximately 29,000 IBD patients showed 1.6-fold increased risk for CAD, in particular in the first year following the diagnosis of the disease. 9 This study, however, did not take into account two major CVD risk factors, smoking and obesity.
Surrogates of CVD risk are increasingly used not only in the research context, but also in clinical practice. Carotid intima-media thickness, reflecting early changes in the arterial wall, is strongly associated with CVD risk, but studies in patients with IBD have been inconclusive. 10 Endothelial dysfunction has been demonstrated in both adult and paediatric patients with IBD by assessing brachial artery flow-mediated vasodilatation, which was lower in IBD patients compared to healthy controls. 11, 13 Arterial stiffness is another surrogate marker of atherosclerosis and an important predictor of CVD events. 14 Arterial stiffness is increased when the elastic properties of the arterial wall are reduced, resulting mainly from the replacement of elastin with collagen and vascular smooth muscle cell hypertrophy. These changes accelerate atherogenesis. 15 Pulse wave velocity (PWV), i.e. the speed at which the pressure waveform travels along the aorta and large arteries during each cardiac cycle, is the gold standard for the assessment of arterial stiffness. Carotid-femoral PWV is the most commonly used measurement. 16 Augmentation index (AIx) represents the extra pressure caused by pressure wave reflection back from the periphery. It is influenced not only by arterial stiffness but also mostly by the intensity of wave reflections. AIx is an indirect surrogate of arterial stiffness.
14 Lipoprotein-associated phospholipase A2 (Lp-PLA2) is a member of the superfamily of phospholipase A2, enzymes that hydrolyze the sn-2 ester bond of phospholipids containing a short acyl chain at the sn-2 position of the glycerol backbone such as platelet-activating factor and oxidized phospholipids. 17, 18 Such phospholipids are accumulated in the artery wall and may play key roles in vascular inflammation and atherosclerosis. Lp-PLA2 is highly expressed in the necrotic core of the atheromatous plaque, playing a key role in the hydrolysis of oxidized phospholipids and generation of the pro-inflammatory and pro-atherogenic products lysophosphatidylcholine and oxidized fatty acids. 19 Lp-PLA2 is secreted by macrophages and other inflammatory cells in the arterial wall, and circulates in plasma associated with lipoproteins. 17, 20 When released into the circulation, the majority of Lp-PLA2 is bound to low density lipoprotein (LDL), 21 being preferentially associated with the atherogenic small, dense LDL particles. 22 Lp-PLA2 is positively associated with the risk of CAD and CAD events. 23 Lp-PLA2 is only weakly associated with markers of systemic inflammation and is considered a more specific marker of inflammation within the arterial wall. 24 Due to the latter, Lp-PLA2 is likely a more accurate surrogate of CVD risks in patients with chronic inflammatory disorders, compared to other markers, such as CRP, that reflect systemic inflammation. 25 The aim of our study was to: a) assess PWV and Lp-PLA2 activity in a group of patients with IBD compared with a control group, b) compare patients with Crohn's disease (CD) and ulcerative colitis (UC) with regard to PWV and Lp-PLA2 activity, and c) assess factors associated with PWV and Lp-PLA2 activity.
Materials and methods

Patients and controls
Forty-four consecutive patients with IBD, 29 with CD and 15 with UC were recruited from the IBD Outpatient Clinic at the Hippokration General Hospital, Thessaloniki, Greece. The diagnosis of IBD had been made using clinical, laboratory, radiological, endoscopic and histological criteria. Only patients between 18 and 60 years of age were included in the study. Exclusion criteria were history of CAD, peripheral artery or cerebrovascular disease, diabetes mellitus, chronic renal failure, familial dyslipidaemias, collagen tissue diseases and total proctocolectomy for UC.
The control group included 44 subjects without IBD matched for gender, age (± 4 years), body mass index (BMI ± 3 kg/m 2 ), and smoking status. The same exclusion criteria were applied to controls.
All participants gave a detailed medical history and underwent physical examination; blood pressure (BP) was measured using an electronic sphygmomanometer; and body weight and height were recorded. Blood samples were obtained after overnight fast, and the following parameters were measured: haemoglobin, white blood cells, platelets, CRP, total cholesterol, high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), triglycerides, vitamin B12, folic acid, and homocysteine. Serum samples were stored at −20°C in order to measure Lp-PLA2. The Lp-PLA2 activity in total plasma was determined by the trichloroacetic acid precipitation procedure using [3H]-PAF (100 μmol/L final concentration) as a substrate. 26 The reaction was performed for 10 min at 37°C. Lp-PLA2 activity was expressed as nmol PAF degraded per min per mL of plasma. As a significant proportion of Lp-PLA2 is associated to LDL-C, the Lp-PLA2-to-LDL-C ratio was calculated to obviate the effect of different LDL-C levels.
The study protocol was approved by the Aristotle University Ethics Committee, and all participants signed an informed consent form before inclusion in the study.
IBD activity
The following IBD parameters were recorded: disease duration, extent of intestinal involvement (left-sided colitis, extensive colitis and pancolitis for UC; terminal ileitis, colitis, both terminal ileitis and colitis for CD), previous intestinal surgery, and number of flares in the last 2 years. In an effort to define disease pattern, we arbitrarily classified overall disease activity as mild, moderate and severe, if there were up to 1, 2-3 and more than 3 flares, respectively, during the last 2 years. With regard to current disease activity, the Mayo score was calculated in patients with UC and the Crohn's Disease Activity Index (CDAI) in those with CD. 27, 28 Remission was defined as CDAI ≤ 150 for CD or Mayo score ≤ 2 for UC. Current medical treatment was also recorded.
CVD risk factors
The following established CVD risk factors were recorded: age, gender, cigarette smoking, hypertension, dyslipidaemia, obesity and family history of premature CVD. Smokers were further classified as light smokers (b 20 pack years) or moderate-heavy smokers (N 20 pack years) in keeping with the WHO classification (http://www.who.int/tobacco/en/). Non-smokers were classified as never-smokers and former-smokers. Cut-off levels for BP and lipid levels were determined in accordance with respective guidelines, 29, 30 corresponding to a low risk population such as the one in our study. The cut-off used for systolic BP was 140 mm Hg and for diastolic BP 90 mm Hg. 30 Mean arterial pressure (MAP) was calculated using the formula MAP =diastolic BP + (systolic BP − diastolic BP) / 3. The cut-off used for total cholesterol was 200 mg/dL, 40 mg/dL for HDL-C and 130 mg/ dL for LDL-C. 29 The use of antihypertensive and lipid-lowering agents was included in the definition of hypertension and dyslipidaemia, respectively. BMI was calculated as kg/m 2 . Family history of premature CVD was defined as CVD in a male first-degree relative b 55 years or in a female first-degree relative b 65 years. 31 Subjects with diabetes mellitus were excluded.
Arterial stiffness
Carotid-femoral PWV and AIx were assessed using the SphygmoCor system (ArtCor, Sydney, Australia). With the subject in the supine position and after 15-minute rest, pressure waveforms were obtained transcutaneously at the right common carotid artery and subsequently at the right femoral artery using an applanation tonometer. Electrocardiogram recording was obtained simultaneously. The distance between the carotid location and the sternal notch, and between the sternal notch and the femoral location, was measured using a flexible tape. The appropriate adjustments were made for subjects with abdominal obesity and women with high bust size. PWV was calculated as the distance between carotid and femoral recording sites divided by the time delay (transit time) between the feet of the carotid and femoral pressure waveforms (foot-to-foot method), determined in relation to the R-wave of the electrocardiogram. To assess AIx the right radial artery waveform was recorded using applanation tonometry and then a transfer function was applied to calculate the aortic pressure waveform. AIx was defined as the difference between the second and first systolic peak expressed as the percentage of the pulse pressure.
Statistical analysis
For a difference in mean PWV of 0.6 m/s between patients and controls (difference in PWV shown in a previous study 32 ), statistical significance a = 0.05, and statistical power 0.9, the calculated sample size was 76, 38 in each group. Data were expressed as mean and standard deviation (SD) for continuous and normally distributed variables, median and range for continuous variables without normal distribution, or frequencies (percentage) for categorical variables. We compared patients with controls, as well as CD patients with UC patients, with regard to established CVD risk factors, laboratory parameters and PWV. For comparisons the chi-square test was used for categorical variables, the Student's t test and the Mann-Whitney test for continuous variables with or without normal distribution, respectively. For comparisons among more than 2 groups the one-way ANOVA and the Kruskal-Wallis test were applied for continuous variables with and without normal distribution, respectively. Pearson (r) and Spearman (rho) correlation coefficient were used to assess correlations between Lp-PLA2, PWV and different variables. Linear regression was applied to assess if the set of the variables that showed significant correlation could predict Lp-PLA2 and PWV, and to identify which one of them was the best predictor of Lp-PLA2 and PWV. The assumptions of multicollinearity, singularity, normality, linearity, homoscedasticity, and independence of residuals were checked before applying linear regression. The level of statistical significance was set at p ≤ 0.05. Statistical analysis was performed using the Statistical Package for Social Sciences, version 20 (SPSS, IL, Chicago).
Results
IBD patients and controls
Among the 88 participants there were 44 men (50%), 22 in each group. The mean age was 36.1 ± 10.3 years in the IBD group and 37.2 ± 10.7 years in the control group. There were 18 smokers in each group (40.9%), with approximately two thirds being moderate-heavy smokers. One third of the non-smokers were ex-smokers, while the rest had never smoked. The median BMI was 23.7 kg/m 2 in the IBD group and 24.3 kg/m 2 in the control group. The proportion of subjects with high blood pressure, high total cholesterol and LDL-C, and low HDL-C levels was similar in the two groups. Although more patients than controls had history of premature CVD, the difference was not significant. Established CVD risk factors for IBD patients and controls are shown in Table 1 .
IBD patients had significantly higher platelet count (median 277 vs 227 × 10 9 /L; p = 0.001), and lower haemoglobin (12.8 ± 2.5 vs 14 ± 1.3 g/dL; p = 0.016), total cholesterol (173.6 ± 46.7 vs 201.2 ± 36.3 mg/dL; p = 0.003), LDL-C (106.4 ± 36.4 vs 129.4 ± 31.9 mg/dL; p = 0.003) and folic acid levels (median 5.1 vs 6.8 ng/mL; p = 0.007). There was no significant difference in white cell count, CRP, HDL-C, triglycerides, vitamin B12 and homocysteine levels. Laboratory results for patients and controls are shown in Table 2 .
Total plasma Lp-PLA2 activity was significantly lower in patients compared with controls (46.8 ± 12.2 vs 53.9 ± 13.5 nmol/mL/min; p = 0.011), but when the Lp-PLA2 was adjusted to LDL-C levels the difference was not significant (Lp-PLA2/LDL-C 0.44 vs 0.42; p = 0.174).
PWV was 6.8 ± 1.2 m/s in IBD patients and 6.4 ± 0.9 m/s in controls, and the AIx was 12.3 ± 15 and 13.8 ± 16.2%, respectively. These differences were not statistically significant.
Patients with CD and UC
The mean disease duration was 8.4 ± 7.2 years, 63.6% of patients had mild overall disease activity, and 72.7% were in remission at the time of the study. Disease duration, disease pattern and rates of remission were similar in patients with CD and UC. Nine patients with CD had previous intestinal resections, whereas none of the UC patients had history of intestinal surgery. Significantly more patients with UC were on 5-aminosalicylates (5-ASA) compared to those with CD (86.7% vs 27.6%; p = 0.001). There was no difference with regard to the use of azathioprine, anti-tumour necrosis factor-a (anti-TNF-a) agents and corticosteroids in the two groups (Table 3 ).
There was no difference in traditional CVD risk factors between the two groups, with the exception of smoking; 58.6% of CD patients were smokers, with the majority being moderate-heavy smokers, whereas only one UC patient (6.7%) smoked (Table 4) .
Patients with CD had significantly lower vitamin B12 (median 266 vs 402.5 pg/mL; p = 0.017) and folic acid levels (median 4.4 vs 6 ng/mL; p = 0.017). The rest of the laboratory investigations were similar in the two groups (Table 5) .
Median total plasma Lp-PLA2 activity was 43.2 nmol/mL/ min in the CD group and 47 nmol/mL/min in the UC group, and the Lp-PLA2/LDL-C ratio was 0.49 and 0.44, respectively. These differences were not statistically significant.
Carotid-femoral PWV was significantly higher in the CD group compared to UC (7 ± 1.2 vs 6.3 ± 1.2 m/s; p = 0.044). AIx was also higher in the same group, although the difference did not reach statistical significance (15.2 ± 14.6 vs 6.9 ± 14.5%; p = 0.081). PWV was significantly higher in CD patients compared to controls (p = 0.006), but was similar in patients with UC and controls.
There was no difference in Lp-PLA2 activity and PWV in the different treatment and disease activity groups, as shown in Table 6 . 
Predictors of Lp-PLA2 ad PWV
Parameters that correlated with Lp-PLA2 activity were white cell count (r = 0.212, p = 0.047), haemoglobin (r = 0.238, p = 0.026), CRP (rho = −0.365, p = 0.003), and LDL-C (r = 0.524, p b 0.0005). In the linear regression only LDL-C remained significant predictor of Lp-PLA2 (beta = 0.475, p b 0.0005) ( Table 7 Table 8 ).
Discussion
Our study showed no difference in arterial stiffness, as assessed by carotid-femoral PWV, between IBD patients without CVD or diabetes mellitus and a strictly matched for age, gender, BMI and smoking habits control group. Lp-PLA2 activity was significantly lower in patients with IBD compared to controls, likely reflecting the lower LDL-C in the former. PWV was significantly higher in patients with CD compared to those with UC and controls. There was no difference in Lp-PLA2 between CD and UC patients. Age, MAP and smoking were associated with PWV, and LDL-C was associated with Lp-PLA2.
A previous study that assessed arterial stiffness in adult patients with IBD showed increased carotid-femoral PWV in IBD patients compared with a group of healthy controls (6.6 ± 1.4 m/s vs 6 ± 0.8, p b 0.05). This study included 32 patients with IBD (16 with CD and 16 with UC), 18-49 years old, without CVD risk factors. 32 The majority of patients (88%) were in remission at the time of the evaluation. However, no data were provided on disease pattern, such as the number and severity of flares in the past, and the extent of intestinal involvement. The inflammatory burden incorporates several components such as the extent of intestinal involvement, disease duration and activity, and can be modified by treatment that suppresses intestinal inflammation. It is likely that higher inflammatory burden is associated with higher CVD risk. In addition, although current smokers were excluded from the study, there were no data on the proportion of ex-smokers, which may have accounted for the difference in PWV, as smoking has a well-known impact on endothelial function and arterial wall properties.
A recent study in 37 patients with UC demonstrated increased carotid-femoral PWV compared to 30 healthy controls (8.9 ± 3 vs 7.2 ± 1.7 m/s; p = 0.004). 33 The control group, however, was not matched to IBD patients for CVD risk factors; it is likely that different constellations of risk factors may account for different CVD risk. In addition, there were more men in the UC group. Gender was associated with PWV in our study. Finally, the main difference from our study is the inclusion of patients with active disease in the above study, whereas in our study the majority of patients were in remission at the time of the evaluation. It has been demonstrated that acute inflammation can have a transient impact on arterial properties, compromising wall compliance and increasing stiffness. 34 Therefore, it might be more accurate to evaluate arterial stiffness in patients in remission, rather than in the acute phase, in order to assess the impact of the chronic inflammatory process and not the impact of an acute exacerbation.
In our study 73% of IBD patients were in remission, but most importantly 64% had mildly active disease pattern, as assessed by the number of flares during the last two years. Furthermore, a significant proportion of patients were treated with infliximab, a highly potent anti-inflammatory agent, which may have accounted for lower inflammatory burden in our study group. Finally, LDL-C, a cardinal CVD risk factor, was significantly lower in patients with IBD. Low LDL-C levels in IBD patients might be the result of intestinal malabsorption, in particular in those with CD, dietary habits or the effect of chronic inflammation on lipid concentrations. 35 The above parameters, i.e. low inflammatory burden and lower LDL-C, should be taken into consideration in order to interpret the lack of difference in arterial stiffness between IBD patients and controls in our study.
Another interesting finding is the increased PWV in patients with CD compared to both patients with UC and controls. There was no difference in disease characteristics in the two groups, but there was a striking difference in smoking habits. More than half of CD patients were active smokers, with the majority being moderate-heavy smokers, whereas only one UC patient was an active smoker. There was no difference in the proportion of former smokers. This difference may contribute to the increased PWV among patients with CD, as smoking was an independent predictor of PWV in multivariate analysis. Smoking has an effect on plasma lipoprotein concentrations, vascular inflammation, endothelial function and arterial stiffness. 36 It is well-known that IBD patients exhibit distinct smoking patterns. Smoking seems to have a beneficial effect on intestinal inflammation in UC, and its cessation has been associated with exacerbations of intestinal inflammation and increased risk of colectomy. 37 In contrast, in CD smoking may be associated with disease flares. 38 A study in 820 patients with IBD showed increased prevalence of smoking among CD patients, whereas UC patients were more likely to be non-smokers or ex-smokers. 39 These differences in smoking rates may account for increased CVD risk in certain subgroups of IBD patients. 40 Another important parameter is the use of 5-ASA. In the large Danish cohort, the incidence of CAD was lower in patients treated with 5-ASA. 9 The lower risk may be attributable to a potential antiplatelet effect of these agents. In our study, the majority of patients with UC were receiving 5-ASA, compared to only one forth of patients with CD, although there was no difference in the use of other anti-inflammatory agents or disease activity. The potential protective effect of 5-ASA and the lower smoking rates may interpret the lower arterial stiffness in patients with UC. Lp-PLA2, a specific biomarker of vascular inflammation and an independent predictor of CVD, has not been studied in patients with IBD. Another member of the PLA2 superfamily, secretory group II PLA2, is involved in intestinal inflammation in IBD, with several studies showing increased concentrations of this enzyme in both the intestinal mucosa and serum in patients with IBD. 41, 42 Secretory PLA2, although associated with CVD risk, is an acute-phase reactant being induced by inflammatory cytokines, therefore is a suboptimal marker of CVD in patients with chronic inflammatory diseases. 18 Lp-PLA2 on the other hand is a specific marker of arterial wall inflammation and is not affected by extravascular inflammation, a property that is particularly important in patients with IBD and intestinal inflammation. No previous study has assessed Lp-PLA2 in patients with IBD.
Lp-PLA2 in the systemic circulation is 80% bound to LDL-C. In our study, IBD patients had lower Lp-PLA2 levels, which paralleled the lower LDL-C levels. It could be hypothesized that lower LDL-C levels lower the CVD risk in IBD patients, even though inflammation precipitates changes in lipid concentrations that are thought to be pro-atherogenic, such as lower HDL-C. In our study there was no difference in HDL-C and triglyceride levels between patients and controls, and in addition the majority of our patients were in remission. Therefore, it could be supported that lower LDL-C levels were the result of more "healthy" dietary habits.
Although the hypothesis of increased CVD risk in IBD that parallels the paradigm of rheumatological diseases is compelling, the results of our study do not support it. Patients with IBD exhibit some unique features such as smoking pattern, lower BMI, and dietary habits, which may alter this association. The exception of patients with CD is most likely attributable to the high rates of smoking among them. Another possible explanation is that our study included mainly patients with mildly active disease pattern, a significant proportion of which received highly potent anti-inflammatory agents, and, thus, with lower inflammatory burden, that may have accounted for the low CVD risk. A study in patients with rheumatoid arthritis showed that anti-TNFa therapy results in a decrease in PWV. 44 Patients with longer disease duration, extensive intestinal involvement, and more aggressive disease activity might be at increased for CVD, due to the higher inflammatory burden.
In order to elucidate a potential association between IBD and CVD risk, prospective studies with sufficient number of patients and long-term follow-up are needed. In addition, thorough assessment of traditional CVD risk factors, as well as patient stratification according to type of disease, inflammatory burden, and type of treatment, is required.
In conclusion, our study showed lower Lp-PLA2 activity in patients with IBD compared with controls, while there was no difference in arterial stiffness between the two groups. Mild disease activity, the use of highly potent anti-inflammatory agents and low LDL-C levels may have ameliorated the effect of chronic inflammation on endothelial function. Patients with CD had higher arterial stiffness compared to UC patients and controls, but this is likely related to high prevalence of smoking among the former. Future studies should include patients with more severe disease activity and thus higher inflammatory burden.
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